ArticleFrontiers in immunology2026
Transdermal entry of a non-pathogenic filamentous fungus
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The immune response to non-pathogenic fungi entering the skin remains largely unknown. In this study, we focused on the fermentative filamentous fungus Methods: Mice were subcutaneously inoculated with the Ao conidia and skin-draining lymph nodes were harvested over time for flow cytometry to evaluate various immune cell subsets. Quantitative reverse transcription-PCR was also conducted to assess the cytokine expression (IFN-γ, IL-4, IL-6, IL-10, IL-12, IL-17, TGF-β, TNF-α) at 4 or 7 days after Ao inoculation. To detect antigen-specific antibody production, mice were immunized with Ao and/or ovalbumin in aluminum hydroxide adjuvant, and sera were collected at day -1, 14, and 35 for ELISA. Fluorescence immunohistostaining was employed to visualize the structural reorganization of the lymph nodes. Active cutaneous anaphylaxis reaction was assessed for the impact of Ao inoculation on allergic response. Results: We observed a marked enlargement of skin-draining lymph nodes and increased immune cell numbers within days. Notably, this was characterized by a marked increase in the number of activated B cells and type 2 resident dendritic cells. These responses were partially reproduced by Ao cell wall components and purified β-glucans; the Ao-dependent downregulation of Dectin-1 expression on dendritic cells supports these findings. However, live Ao elicited the most pronounced lymph node response, as heat inactivation and the cell wall fraction clearly attenuated it, suggesting that other components are also necessary. Ao appears to induce a relatively mild response in the lymph nodes, characterized by a marked increase in IL-4 expression, whereas other cytokines were suppressed or unaltered. In the long term, Ao entry elicited immune memory with antibody production specific to the conidial proteins and β-glucan, although it did not enhance the antibody against another antigen/adjuvant. Furthermore, we found that pre-inoculation with Ao inhibited allergic responses. This is consistent with the novel effects of Ao inoculation, which reduces the CD301b Conclusion: Transdermal Ao entry clearly induces adaptive immunity in draining lymph nodes. However, the response is not necessarily intense and shows an immunomodulatory aspect with less harmful or even beneficial effects, potentially suppressing allergic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.